Lasers in surgery and medicine · 2025
Adjunctive Pulsed Dye Laser Therapy for Paronychia Induced by Anticancer Agents.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pruangmethangkul Thunyaporn, Pongprutthipan Marisa, Chottawornsak Natcha, Kerr Stephen J, Rerknimitr Pawinee
Аннотация
BACKGROUND: Paronychia is a common side effect of anticancer therapies, particularly epidermal growth factor receptor inhibitors (EGFRIs). Standard treatments often provide limited relief. Pulsed dye laser (PDL) therapy at 595 nm, with vascular-targeting and anti-inflammatory effects, may serve as an effective adjunctive treatment.
OBJECTIVE: To evaluate the clinical efficacy and safety of adjunctive 595-nm PDL therapy in the treatment of paronychia induced by anticancer drugs, particularly EGFRIs.
MATERIALS AND METHODS: This prospective pre-post study included 70 digits with anticancer drug-induced paronychia, Common Terminology Criteria for Adverse Events [CTCAE] grade 1-2, from ten patients. After a 2-week run-in with standardized treatment, participants received 4 weekly sessions of 595-nm PDL therapy. Outcomes-assessed at baseline, each visit, and 2 weeks posttreatment-included erythema index (EI), modified Severity of Paronychia Assessment Tool (SPOT) score, pain, edema, Physician Global Assessment (PGA), patient satisfaction, and adverse events.
RESULTS: PDL therapy significantly reduced the EI from 1.63 to 1.42 (p < 0.001) and edema from 1.67 to 1.45 (p < 0.001). Modified SPOT scores improved from 3.61 to 1.99 (p < 0.001), with early pain relief observed (4.40-1.25; p < 0.001). PGA improved by Week 3, and patient satisfaction increased from 0 to 100 by Week 5 (p < 0.001).
CONCLUSION: PDL adjuvant therapy significantly improves both clinical signs and patient-reported outcomes in anticancer drug-induced paronychia.
OBJECTIVE: To evaluate the clinical efficacy and safety of adjunctive 595-nm PDL therapy in the treatment of paronychia induced by anticancer drugs, particularly EGFRIs.
MATERIALS AND METHODS: This prospective pre-post study included 70 digits with anticancer drug-induced paronychia, Common Terminology Criteria for Adverse Events [CTCAE] grade 1-2, from ten patients. After a 2-week run-in with standardized treatment, participants received 4 weekly sessions of 595-nm PDL therapy. Outcomes-assessed at baseline, each visit, and 2 weeks posttreatment-included erythema index (EI), modified Severity of Paronychia Assessment Tool (SPOT) score, pain, edema, Physician Global Assessment (PGA), patient satisfaction, and adverse events.
RESULTS: PDL therapy significantly reduced the EI from 1.63 to 1.42 (p < 0.001) and edema from 1.67 to 1.45 (p < 0.001). Modified SPOT scores improved from 3.61 to 1.99 (p < 0.001), with early pain relief observed (4.40-1.25; p < 0.001). PGA improved by Week 3, and patient satisfaction increased from 0 to 100 by Week 5 (p < 0.001).
CONCLUSION: PDL adjuvant therapy significantly improves both clinical signs and patient-reported outcomes in anticancer drug-induced paronychia.